179 related articles for article (PubMed ID: 32503616)
1. Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS).
Zheng B; Hudson M; Wang M; Baron M;
Arthritis Res Ther; 2020 Jun; 22(1):132. PubMed ID: 32503616
[TBL] [Abstract][Full Text] [Related]
2. Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures.
Zheng B; Wang M; Stevens W; Proudman S; Nikpour M; Baron M; ;
Semin Arthritis Rheum; 2022 Apr; 53():151973. PubMed ID: 35149318
[TBL] [Abstract][Full Text] [Related]
3. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Spiera R; Kuwana M; Khanna D; Hummers L; Frech TM; Stevens W; Matucci-Cerinic M; Kafaja S; Distler O; Jun JB; Levy Y; Leszcyzński P; Gordon J; Steen V; Lee EB; Jankowski T; Litinsky I; Chung L; Hsu V; Mayes M; Sandorfi N; Simms RW; Finzel S; de Vries-Bouwstra J; Constantine S; Dgetluck N; Dinh Q; Bloom BJ; Furst DE; White B; Denton CP;
Arthritis Rheumatol; 2023 Sep; 75(9):1608-1618. PubMed ID: 37098795
[TBL] [Abstract][Full Text] [Related]
5. Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis.
Zheng B; Wang M; McKenna K; Shapiro L; Silver R; Csuka ME; van den Hoogen F; Robinson D; Pauling JD; Hummers L; Krieg T; Del Galdo F; Spiera R; Jones N; Khalidi N; Vacca A; de Vries-Bouwstra JK; Gordon J; Baron M;
Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1806-1812. PubMed ID: 38662853
[TBL] [Abstract][Full Text] [Related]
6. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
[TBL] [Abstract][Full Text] [Related]
7. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
Khanna D; Berrocal VJ; Giannini EH; Seibold JR; Merkel PA; Mayes MD; Baron M; Clements PJ; Steen V; Assassi S; Schiopu E; Phillips K; Simms RW; Allanore Y; Denton CP; Distler O; Johnson SR; Matucci-Cerinic M; Pope JE; Proudman SM; Siegel J; Wong WK; Wells AU; Furst DE
Arthritis Rheumatol; 2016 Feb; 68(2):299-311. PubMed ID: 26808827
[TBL] [Abstract][Full Text] [Related]
8. Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database.
Allanore Y; Bozzi S; Terlinden A; Huscher D; Amand C; Soubrane C; Siegert E; Czirják L; Carreira PE; Hachulla E; Zanatta E; Li M; Airò P; Mendoza FA; Rosato E; Distler O;
Arthritis Res Ther; 2020 Oct; 22(1):257. PubMed ID: 33115544
[TBL] [Abstract][Full Text] [Related]
9. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
Khanna D; Berrocal VJ; Giannini EH; Seibold JR; Merkel PA; Mayes MD; Baron M; Clements PJ; Steen V; Assassi S; Schiopu E; Phillips K; Simms RW; Allanore Y; Denton CP; Distler O; Johnson SR; Matucci-Cerinic M; Pope JE; Proudman SM; Siegel J; Wong WK; Wells AU; Furst DE
Arthritis Care Res (Hoboken); 2016 Feb; 68(2):167-78. PubMed ID: 26806474
[TBL] [Abstract][Full Text] [Related]
10. A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials.
Domsic RT; Medsger TA; Gao S; Laffoon M; Huang S; Wisniewski S; Spino C; Steen V; Lafyatis R; Khanna D
Rheumatology (Oxford); 2023 Apr; 62(4):1543-1551. PubMed ID: 36031807
[TBL] [Abstract][Full Text] [Related]
11. Do We Have Good Activity Indices in Systemic Sclerosis?
Groseanu L; Petrescu S; Balanescu A; Bojinca V; Opris-Belinski D; Berghea F; Mazilu D; Saulescu I; Borangiu A; Daia-Iliescu S; Constantinescu C; Cobilinschi C; Abobului M; Negru MM; Ionescu R
Curr Rheumatol Rev; 2022; 18(1):39-47. PubMed ID: 34517805
[TBL] [Abstract][Full Text] [Related]
12. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.
Merkel PA; Silliman NP; Clements PJ; Denton CP; Furst DE; Mayes MD; Pope JE; Polisson RP; Streisand JB; Seibold JR;
Arthritis Rheum; 2012 Oct; 64(10):3420-9. PubMed ID: 22328195
[TBL] [Abstract][Full Text] [Related]
13. New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis.
Khanna D; Huang S; Lin CJF; Spino C
Ann Rheum Dis; 2021 May; 80(5):641-650. PubMed ID: 33257497
[TBL] [Abstract][Full Text] [Related]
14. Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity.
Zheng B; Nevskaya T; Baxter CA; Ramey DR; Pope JE; Baron M;
Rheumatology (Oxford); 2020 Feb; 59(2):398-406. PubMed ID: 31359048
[TBL] [Abstract][Full Text] [Related]
15. Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis.
Mendoza FA; Lee-Ching C; Jimenez SA
Semin Arthritis Rheum; 2020 Feb; 50(1):135-139. PubMed ID: 31311679
[TBL] [Abstract][Full Text] [Related]
16. High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome.
Wannarong T; Muangchan C
Rheumatol Int; 2018 Dec; 38(12):2279-2288. PubMed ID: 30206672
[TBL] [Abstract][Full Text] [Related]
17. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort.
Jaafar S; Lescoat A; Huang S; Gordon J; Hinchcliff M; Shah AA; Assassi S; Domsic R; Bernstein EJ; Steen V; Elliott S; Hant F; Castelino FV; Shanmugam VK; Correia C; Varga J; Nagaraja V; Roofeh D; Frech T; Khanna D
Arthritis Res Ther; 2021 Jun; 23(1):170. PubMed ID: 34127049
[TBL] [Abstract][Full Text] [Related]
19. Clinical course of Japanese patients with early systemic sclerosis: A multicenter, prospective, observational study.
Utsunomiya A; Hasegawa M; Oyama N; Asano Y; Endo H; Fujimoto M; Goto D; Ishikawa O; Kawaguchi Y; Kuwana M; Ogawa F; Takahashi H; Tanaka S; Sato S; Takehara K; Ihn H
Mod Rheumatol; 2021 Jan; 31(1):162-170. PubMed ID: 32243215
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.
Namas R; Tashkin DP; Furst DE; Wilhalme H; Tseng CH; Roth MD; Kafaja S; Volkmann E; Clements PJ; Khanna D;
Arthritis Care Res (Hoboken); 2018 Mar; 70(3):439-444. PubMed ID: 28544580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
